title: Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome.
abstract: The hemolytic uremic syndrome (HUS) is the most common cause of acute renal failure in children. The role of a verocytotoxin (VT)-producing Escherichia coli has been strongly implicated in the epidemic form of HUS. Although direct toxicity of VT on glomerular endothelial cells has been demonstrated, it remained still unclear how the VT is transported from the intestine to the target organs. In this study we demonstrate that VT, when incubated in whole blood, binds rapidly and completely to human polymorphonuclear leukocytes (PMNs) and not to other components of blood. Binding studies with (125)I-VT-1 showed a single class of binding sites on freshly isolated, nonstimulated human PMNs. The K(d) of VT-binding to PMNs was 10(-8) mol/L, 100-fold less than that of the VT-receptor globotriaosylceramide. On incubation of VT-preloaded PMNs with human glomerular microvascular endothelial cells (GMVECs), transfer of VT-1 to the endothelial cells occurred. Incubation of nonstimulated GMVECs with VT-preloaded PMNs, but not with PMNs or VT-1 alone, caused inhibition of protein synthesis and cell death. Our data are in concert with a role of PMNs in the transfer of VT from the intestine to the kidney endothelium. This transfer occurs by selective binding to a specific receptor on PMNs and subsequent passing of the ligand VT to the VT-receptor on GMVECs, which causes cell damage. This new mechanism further underpins the important role of PMNs in HUS.
authors.affiliation: Department of Pediatrics, University Hospital Nijmegen, The Netherlands.
authors.forename: D M
authors.initials: DM
authors.lastname: te Loo
authors.forename: L A
authors.initials: LA
authors.lastname: Monnens
authors.forename: T J
authors.initials: TJ
authors.lastname: van Der Velden
authors.forename: M A
authors.initials: MA
authors.lastname: Vermeer
authors.forename: F
authors.initials: F
authors.lastname: Preyers
authors.forename: P N
authors.initials: PN
authors.lastname: Demacker
authors.forename: L P
authors.initials: LP
authors.lastname: van Den Heuvel
authors.forename: V W
authors.initials: VW
authors.lastname: van Hinsbergh
mesh_terms: D000328:Adult; D001427:Bacterial Toxins / Q000097:blood* / Q000493:pharmacokinetics; D002648:Child; D004730:Endothelium, Vascular / Q000166:cytology / Q000502:physiology*; D004926:Escherichia coli; D016650:Fluorescein-5-isothiocyanate; D006463:Hemolytic-Uremic Syndrome / Q000097:blood*; D006801:Humans; D066298:In Vitro Techniques; D007457:Iodine Radioisotopes; D007678:Kidney Glomerulus / Q000098:blood supply; D007700:Kinetics; D008074:Lipoproteins / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood; D008833:Microcirculation / Q000502:physiology; D009504:Neutrophils / Q000502:physiology*; D011956:Receptors, Cell Surface / Q000097:blood; D022622:Shiga Toxin 1; D014281:Trihexosylceramides / Q000097:blood
chemical_list: D001427:Bacterial Toxins; D007457:Iodine Radioisotopes; D008074:Lipoproteins; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D011956:Receptors, Cell Surface; D022622:Shiga Toxin 1; D014281:Trihexosylceramides; C018549:globotriaosylceramide; D016650:Fluorescein-5-isothiocyanate